Komori
Mitsubishi Chemical Group (4188) · FactReframed

Holding-company structure overseeing 3 business fields and 6 operating companies

First written in FY2016. 9 of 18 entries say "Reframed", first in FY2017. Latest entry: FY2027-H1.

18entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018-Q3 – FY2021ReframedFY2022-Q1 – FY2022ReframedFY2024-Q1 – FY2025-H12016: 120162017: 220172018: 220182019: 220192020: 120202021: 220212022: 120222023: 220232024: 120242025: 220252026: 22026
Same theme, other companies
Holding company structure overseeing the 3 fields of Functional Products, Healthcare and MaterialsA theme 1 companies write about · 0 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2027-H1ReframedAnnual report

    「In April 2026, the Company reorganized its business divisions from the perspectives of markets and business models to establish a structure in which the business divisions operate their businesses with ownership and can make decisions more quickly. In line with this reorganization, the Company reviewed its reportable segments from the current interim consolidated accounting period, changing them from the former 4 categories—Specialty Materials, MMA & Derivatives, Basic Materials & Polymers and Industrial Gases—to 4 categories: Specialty Materials, MMA & Derivatives, Basic Materials and Industrial Gases.」

    In line with the organizational reform of April 2026, the Company maintained 4 reportable segments but changed Basic Materials & Polymers to Basic Materials.
  2. FY2026ReframedAnnual report

    「The corporate venture capital business and related activities conducted by the Company were transferred by absorption-type company split, changing from the Company to Mitsubishi Chemical Corporation, its wholly owned direct subsidiary.」

    Effective 1 April 2026, the Company reorganized its organizational structure by transferring the corporate venture capital business and other businesses previously handled by the holding company to operating companies.
  3. FY2026-H1ReframedAnnual report

    「Following the classification of the businesses of Tanabe Mitsubishi Pharma Corporation and its subsidiaries and affiliates as discontinued operations, the Company reports 4 segments from the current interim consolidated fiscal period: Specialty Materials, MMA & Derivatives, Basic Materials & Polymers, and Industrial Gases.」

    Following the transfer of 田辺三菱製薬㈱ and its classification as a discontinued operation, the Company reorganized its reportable segments from the former 5 categories into 4 categories, excluding Pharma.
  4. FY2025AdvancedAnnual report

    「Under the New Medium-Term Management Plan 2029, we changed to a new structure in which our company, as the holding company, is responsible for formulating group-wide strategy, optimally allocating management resources and overseeing business management, while the operating companies are responsible for managing their respective businesses.」

    The Company clarified its transition to a new structure for operating 5 segments, under which the holding company is responsible for Group-wide strategy formulation, resource allocation and business oversight, while the operating companies under it are responsible for business management.
  5. FY2025-H1ReframedAnnual report

    「To further strengthen collaboration among businesses and accelerate growth, the Group implemented an organizational reform effective 1 April 2024. In line with this reorganization, it reorganized the businesses within the reportable segments from the beginning of the current consolidated fiscal year, changing the former 5 categories—Specialty Materials, Industrial Gases, Healthcare, MMA and Basic Materials—to 5 categories: Specialty Materials, Industrial Gases, Pharma, MMA & Derivatives and Basic Materials & Polymers.」

    While maintaining the 5-segment framework, the Company reorganized the business categories within its reportable segments in line with the organizational reform of 1 April 2024, changing Healthcare to Pharma and MMA to MMA & Derivatives, among other changes.
  6. FY2024-Q1ReframedAnnual report

    「From the first quarter of the current consolidated fiscal year, the Company reviewed its reportable segments and changed them from the former 4 categories—Performance Products, Chemicals, Industrial Gases and Healthcare—to 5 categories: Specialty Materials, Industrial Gases, Healthcare, MMA and Basic Materials.」

    The Group’s business structure and reportable segments were changed from 4 categories to 5.
  7. FY2023AdvancedAnnual report

    「The Group comprises the Company, 442 subsidiaries and 151 affiliated companies and other entities. Under the Company, it conducts business activities in 3 fields—Performance Products, Materials and Healthcare—through 4 companies: 三菱ケミカル㈱, 田辺三菱製薬㈱, ㈱生命科学インスティテュート and NIPPON SANSO HOLDINGS CORPORATION.」

    The Company continues to operate 3 fields and 4 segments through 4 directly invested subsidiaries and updated the Group structure to 442 subsidiaries and 151 affiliated companies and other entities. It also consolidated its regional headquarters in North America and Europe.
  8. FY2022ReframedAnnual report

    「In April of this year, the Group launched a structure for efficiently managing the entire Group as “One Company, One Team.”」

    In addition to describing the holding-company structure centered on 4 operating companies, the Company stated that the Group transitioned to a structure for integrated management of the entire Group from April 2022.
  9. FY2022-Q1ReframedAnnual report

    「From the first quarter of the current consolidated fiscal year, in connection with establishing an organizational structure aligned with the growth business areas under the medium- to long-term management strategy KAITEKI Vision 30, the breakdown of Performance Products was changed from the two categories of Functional Materials and Functional Chemicals to the three categories of Polymers & Compounds, Films & Molding Materials, and Advanced Solutions.」

    Under the structure centered on 4 operating companies and 4 business areas, the Company changed the internal classification of Performance Products to 3 categories corresponding to the growth business areas of KAITEKI Vision 30.
  10. FY2021RestatedAnnual report

    「The Group consists of the Company, 506 subsidiaries and 160 affiliates and other associated companies. Through four directly owned subsidiaries under the holding company—Mitsubishi Chemical Corporation, Tanabe Mitsubishi Pharma Corporation, Life Science Institute, Ltd. and Nippon Sanso Holdings Corporation—the Group conducts business in three fields: Performance Products, Materials and Healthcare.」

    The Company continues to operate 3 fields and 4 segments through 4 directly invested subsidiaries. The Group comprises 506 subsidiaries and 160 affiliated companies and other entities.
  11. FY2020RestatedAnnual report

    「The Group consists of the Company, 532 subsidiaries and 166 associated companies and other entities. Under the holding company, the Group conducts business through 4 operating companies—Mitsubishi Chemical Corporation, Tanabe Mitsubishi Pharma Corporation, Life Science Institute, Inc. and Taiyo Nippon Sanso Corporation—in 3 fields: performance products, materials and healthcare.」

    The Company continues to describe a holding-company structure conducting business across 3 fields and 4 segments, centered on 4 operating companies.
  12. FY2020-Q1RestatedAnnual report

    「The Group reports 4 business areas—“Performance Products,” “Chemicals,” “Industrial Gases” and “Healthcare”—in which it operates primarily through 4 operating companies under the holding company: Mitsubishi Chemical Corporation, Tanabe Mitsubishi Pharma Corporation, Life Science Institute, Inc. and Taiyo Nippon Sanso Corporation.」

    The Company continues to describe a holding-company structure conducting business across 4 business areas, centered on 4 operating companies.
  13. FY2019RestatedAnnual report

    「The Group comprises the Company, 580 subsidiaries and 174 affiliated companies and other entities. Under the holding company, the Company conducts business activities in 3 fields—Performance Products, Materials and Healthcare—through 4 operating companies: 三菱ケミカル㈱, 田辺三菱製薬㈱, ㈱生命科学インスティテュート and 大陽日酸㈱.」

    The Company continues to describe a holding-company structure conducting business across 3 fields and 4 segments, centered on 4 operating companies.
  14. FY2019-Q2RestatedAnnual report

    「The Group conducts business in four business areas, namely Performance Products, Chemicals, Industrial Gases and Healthcare, primarily through four operating companies under the holding company: Mitsubishi Chemical Corporation, Tanabe Mitsubishi Pharma Corporation, Life Science Institute, Ltd. and Taiyo Nippon Sanso Corporation.」

    The Company continues to describe a holding-company structure centered on 4 operating companies and 4 business areas.
  15. FY2018-Q3RestatedAnnual report

    「Taking this opportunity, the Company, as the holding company, transitioned to a management structure designed to accelerate its growth strategy by further enhancing the formulation of medium-term strategies and monitoring of medium-term management plans for 4 business areas—Performance Products, Chemicals, Industrial Gases and Healthcare—centered on 4 operating companies: 三菱ケミカル㈱, 田辺三菱製薬㈱, ㈱生命科学インスティテュート and 大陽日酸㈱.」

    The Company continues to describe a holding-company structure centered on 4 operating companies and 4 business areas following the integration of the 3 chemical companies, with the holding company responsible for medium-term strategy formulation and plan monitoring.
  16. FY2018-Q1ReframedAnnual report

    「Taking this opportunity, the Company, as the holding company, transitioned to a management structure designed to accelerate its growth strategy by further enhancing the formulation of medium-term strategies and monitoring of medium-term management plans for 4 business areas—Performance Products, Chemicals, Industrial Gases and Healthcare—centered on 4 operating companies: 三菱ケミカル㈱, 田辺三菱製薬㈱, ㈱生命科学インスティテュート and 大陽日酸㈱.」

    Following the integration of the 3 chemical companies, the Company describes a structure centered on 4 operating companies and 4 business areas, with the holding company responsible for medium-term strategy formulation and plan monitoring.
  17. FY2017ReframedAnnual report

    「Effective 1 April 2017, 三菱化学㈱, 三菱樹脂㈱ and 三菱レイヨン㈱ merged to form 三菱ケミカル㈱. 三菱ケミカル㈱ operates businesses in the Electronics Applications, Designed Materials, Chemicals, Polymers and Other segments.」

    The Group transitioned from a structure centered on the former 6 operating companies to one in which 3 chemical companies were integrated into 三菱ケミカル㈱.
  18. FY2016First statedAnnual report

    「The Group has adopted a holding company structure and conducts its business primarily through 6 operating companies under the holding company, namely Mitsubishi Chemical Corporation, Tanabe Mitsubishi Pharma Corporation, Mitsubishi Plastics, Inc., Mitsubishi Rayon Co., Ltd., Life Science Institute, Inc. and Taiyo Nippon Sanso Corporation.」

    The Company operates across 3 fields—Performance Products, Healthcare and Materials—centered on 6 core operating companies.
Moved together

"Earnings volatility arising from demand, market conditions, raw material prices, foreign exchange and supply constraints" moved the same way as this thread, in the same document, in 6 of its 18 moves.

654333★123456
  1. ★This thread
  2. 1Earnings volatility arising from demand, market conditions, raw material prices, foreign exchange and supply constraints6×
  3. 2Deteriorating profitability and impairment at petrochemical and materials facilities5×
  4. 3Geopolitical, regulatory, infrastructure and personnel risks associated with overseas expansion4×
  5. 4Funding risks from interest-bearing debt, interest rates and credit-rating downgrades3×
  6. 5Consolidation of Mitsubishi Chemical’s business units and focus on 5 strategic markets3×
  7. 6Risk of Corporate and Personal Information Leaks3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Mitsubishi Chemical Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.